FLT
FLT (Fms-like tyrosine kinase) inhibitors are compounds that target FLT receptors, which are involved in the regulation of angiogenesis through the VEGF (vascular endothelial growth factor) pathway. FLT receptors play a crucial role in the development of new blood vessels in tumors. Inhibiting FLT receptors can effectively reduce angiogenesis and tumor growth, making these inhibitors important in cancer therapy. At CymitQuimica, we offer a selection of high-quality FLT inhibitors to support your research in oncology, vascular biology, and angiogenesis.
Found 91 products of "FLT"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRX-2843
CAS:MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).Formula:C29H40N6OPurity:98.59% - 99.63%Color and Shape:SolidMolecular weight:488.67Ref: TM-T16144
1mg62.00€5mg138.00€10mg215.00€25mg430.00€50mg622.00€100mg887.00€1mL*10mM (DMSO)148.00€FLT3-IN-3
CAS:FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.Formula:C27H38N8OPurity:99.25%Color and Shape:SolidMolecular weight:490.64Ref: TM-T11298
1mg107.00€5mg259.00€10mg432.00€25mg715.00€50mg1,008.00€100mg1,359.00€500mg2,717.00€1mL*10mM (DMSO)278.00€FLT3/HDAC-IN-2
Compound 25h, also known as FLT3/HDAC-IN-2, is a dual inhibitor of FLT3/HDAC. It exhibits antiproliferative activity against MOLM-13 cells and is used in the study of acute myeloid leukemia.Color and Shape:Odour SolidPROTAC FLT-3 degrader 3
PROTACFLT-3degrader 3 (compound 35) is a PROTAC degrader of FLT. It exhibits antiproliferative activity, with an IC50 value of 7.55 nM in MV4-11 cells.Formula:C48H44Cl2N10O6Molecular weight:926.28223Pacritinib citrate
CAS:Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM). It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM). This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].Formula:C34H40N4O10Color and Shape:SolidMolecular weight:664.72-Butenamide
CAS:2-Butenamide, FLT3 inhibitor. Affordable Excellence: Reliable Quality You Can TrustFormula:C4H7NOColor and Shape:SolidMolecular weight:85.1FLT3-IN-24
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase, with an IC50 of 7.94 nM. It also exhibits anti-proliferative effects on cells.Formula:C23H20N6O2SMolecular weight:444.13685FLT3-IN-20
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.Formula:C28H33N7O2SColor and Shape:SolidMolecular weight:531.67FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formula:C29H35N7O5Color and Shape:SolidMolecular weight:561.63FLT3-ITD-IN-2
FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.Formula:C39H50N8O6Color and Shape:SolidMolecular weight:726.86HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Color and Shape:Odour SolidFLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsColor and Shape:Odour SolidJAK3-IN-14
CAS:JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Formula:C18H13N3OPurity:98.29%Color and Shape:SoildMolecular weight:287.32Ref: TM-T67754
1mg170.00€5mg432.00€10mg628.00€25mg938.00€50mg1,301.00€100mg1,758.00€200mg2,452.00€1mL*10mM (DMSO)378.00€3-Hydroxy Midostaurin
CAS:3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM inFormula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.648FLT3 Ligand-Linker Conjugate 1
CAS:FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formula:C29H34N6O4S2Color and Shape:SolidMolecular weight:594.748PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formula:C46H50F3N13O8Purity:98%Color and Shape:SolidMolecular weight:969.97PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Formula:C44H49N13O6Purity:98%Color and Shape:SolidMolecular weight:855.94PROTAC FLT3/GSPT1/IKZF1/3 degrader-1
PROTACFLT3/GSPT1/IKZF1/3 degrader-1 is an FLT3 PROTAC degrader with DC50 = 1.2 nM. It functions as a molecular glue to degrade its brain substrates and exhibits antiproliferative activity against resistant acute myeloid leukemia (AML) cells, showing potential applications in AML research.Color and Shape:Odour SolidEmirodatamab
CAS:Emirodatamab (AMG-427) is an anti-FLT3/CD3 bispecific T-cell engager with an extended half-life. It can induce high cytotoxicity in primary AML progenitor cells and enhance FLT-3 expression. Combining Emirodatamab with anti-PD-1 antibodies increases T-cell dependent cytotoxicity (TDCC). This compound is under investigation for use in relapsed or refractory AML.
